Literature DB >> 7125407

Vasodilators and prostaglandin inhibitors in primary pulmonary hypertension.

J B Hermiller, D Bambach, M J Thompson, P Huss, M E Fontana, R D Magorien, D V Unverferth, C V Leier.   

Abstract

Ten women with primary pulmonary hypertension had resting hemodynamic measurements taken before and after the nonparenteral administration of various vasodilators and prostaglandin inhibitors. Only sublingual isoproterenol, alone or combined with sublingual isosorbide dinitrate, effected a substantial (greater than 20%) drop in pulmonary vascular resistance; this decrease was accompanied by little change in pulmonary artery pressure. Isosorbide dinitrate was the only drug that elicited any reduction in pulmonary artery pressure; pulmonary vascular resistance decreased modestly. The oral administration of diazoxide, hydralazine, phentolamine, and tolazoline elicited little change in pulmonary artery pressure or resistance. Except for tolazoline, all these agents significantly decreased systemic blood pressure and resistance. Prostaglandin inhibition by indomethacin (acute and chronic dosing) increased pulmonary and systemic vascular resistances and reduced cardiac output. Aspirin combined with dipyridamole elicited no changes. The vasodilators and prostaglandin inhibitors studied evoked little improvement in resting pulmonary hemodynamic abnormalities in primary pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7125407     DOI: 10.7326/0003-4819-97-4-480

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  8 in total

1.  Chest diseases-important advances in clinical medicine: drug therapy for pulmonary hypertension.

Authors:  P M Gold
Journal:  West J Med       Date:  1984-01

Review 2.  Pulmonary hypertension.

Authors:  J R Michael; W R Summer
Journal:  Lung       Date:  1985       Impact factor: 2.584

Review 3.  Pulmonary hypertension in children: perioperative management.

Authors:  F A Burrows; J R Klinck; M Rabinovitch; D J Bohn
Journal:  Can Anaesth Soc J       Date:  1986-09

4.  Management of primary pulmonary hypertension.

Authors:  C M Oakley
Journal:  Br Heart J       Date:  1985-01

5.  Sublingual isoprenaline in treatment of primary pulmonary hypertension: discussion paper.

Authors:  J F Ackroyd
Journal:  J R Soc Med       Date:  1985-06       Impact factor: 5.344

Review 6.  Drug treatment of primary pulmonary hypertension.

Authors:  A A McLeod; D E Jewitt
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

7.  Twelve year clinical study of patients with hypoxic cor pulmonale given long term domiciliary oxygen therapy.

Authors:  C B Cooper; J Waterhouse; P Howard
Journal:  Thorax       Date:  1987-02       Impact factor: 9.139

Review 8.  Haemodynamic responses to specific renin-angiotensin inhibitors in hypertension and congestive heart failure. A review.

Authors:  R J Cody
Journal:  Drugs       Date:  1984-08       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.